Artiva Biotherapeutics (ARTV) Common Equity (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Common Equity data on file, last reported at $87.8 million in Q1 2026.

• On a quarterly basis, Common Equity fell 47.95% year-over-year to $87.8 million in Q1 2026; TTM through Mar 2026 was $87.8 million, a 47.95% decrease from a year earlier, with the FY2025 full-year figure at $110.0 million, down 41.08% from the prior year.
• Common Equity for Q1 2026 stood at $87.8 million, down from $110.0 million in the prior quarter.
• Over the last five years, Common Equity for ARTV reached as high as $201.0 million in Q3 2024 and fell as low as -$191.1 million in Q2 2024.
• Historically, Common Equity has averaged $15.8 million across 4 years, with a median of $98.9 million in 2025.
• Across the five-year window, Common Equity surged 232.71% in 2024 and plunged 47.95% in 2026, its largest moves.
• Year by year, Common Equity stood at -$162.0 million in 2023, then soared by 215.2% to $186.6 million in 2024, then sank by 41.08% to $110.0 million in 2025, then declined by 20.12% to $87.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $87.8 million in Q1 2026, $110.0 million in Q4 2025, and $129.2 million in Q3 2025.